Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on February 8, 2021, covering events occurring between February 8 and February 12, 2021. The Company is a Delaware corporation with its principal executive offices in Charlottesville, VA, and its common stock and warrants trade on the NASDAQ under the symbols ADIL and ADILW, respectively.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on executive compensation, equity awards, and director fee adjustments.
Material Changes and Compensation Actions
Executive Equity Awards (February 8, 2021)
- CEO (William B. Stilley): Granted an option to purchase 250,000 shares.
- CFO (Joseph Truluck): Granted an option to purchase 125,000 shares.
- Directors (Schuyler, Anderson, Newman, Goodman, Gilliland): Each granted an option to purchase 40,000 shares.
- Terms: All options have an exercise price of $3.11 per share, vest pro rata monthly over 36 months, and are exercisable for 10 years.
Executive Cash Bonuses and Employment Amendments (February 12, 2021)
- 2020 Performance Bonuses: CEO received $150,000; CFO received $50,000.
- CEO Employment Agreement: Term extended to March 31, 2026; target bonus increased to 40%.
- CFO Employment Agreement: Term extended to March 31, 2026; target bonus increased to 25%; annual salary increased to $260,000; required working time for Company matters increased to 75%.
Director Fee Adjustments (February 12, 2021)
- Chairman of the Board: Annual fee reduced from $49,000 to $30,000 (position currently vacant).
- Other Directors: Annual Board fee increased from $20,000 to $24,000.
- Committee Chairmen: Fees increased to $16,000 (Audit), $11,000 (Compensation), and $8,000 (Nominating and Governance).
- Committee Members: Fees increased to $8,000 (Audit), $6,000 (Compensation), and $4,000 (Nominating and Governance).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of material risks and contingencies. The Company intends to file the amended employment agreements as exhibits to its Annual Report on Form 10-K for the year ended December 31, 2020.
Key Facts for Investor Verification
- Verify the total dilution impact of the 525,000 new stock options granted to executives and directors.
- Confirm the cash outflow of $200,000 for 2020 performance bonuses paid to the CEO and CFO.
- Review the upcoming Form 10-K for the full text of the amended employment agreements extending terms to 2026.
- Note the reduction in the Chairman of the Board fee, reflecting the current vacancy of that position.